| Dr Romi Shah, MD | |
|
75 Crystal Run Rd Ste 135, Middletown, NY 10941-7009 | |
| (845) 333-7800 | |
| Not Available |
| Full Name | Dr Romi Shah |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 20 Years |
| Location | 75 Crystal Run Rd Ste 135, Middletown, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083149363 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 309413 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ahava Medical And Rehabilitation Center, Llc | 1557416997 | 87 |
| Garnet Health Doctors Pc | 8628293545 | 156 |
News Archive
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
Blue Cross Blue Shield Association and top executives from Blue Cross and Blue Shield companies around the country today committed to addressing the nation's growing opioid crisis with an executive-level committee that will investigate its impact on individuals, local communities and the healthcare system as a whole.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
› Verified 4 days ago
| Entity Name | Ahava Medical And Rehabilitation Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184878274 PECOS PAC ID: 1557416997 Enrollment ID: O20090908000443 |
News Archive
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
Blue Cross Blue Shield Association and top executives from Blue Cross and Blue Shield companies around the country today committed to addressing the nation's growing opioid crisis with an executive-level committee that will investigate its impact on individuals, local communities and the healthcare system as a whole.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
› Verified 4 days ago
| Entity Name | Garnet Health Doctors Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093138851 PECOS PAC ID: 8628293545 Enrollment ID: O20140710000189 |
News Archive
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
Blue Cross Blue Shield Association and top executives from Blue Cross and Blue Shield companies around the country today committed to addressing the nation's growing opioid crisis with an executive-level committee that will investigate its impact on individuals, local communities and the healthcare system as a whole.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
› Verified 4 days ago
| Entity Name | Lebgutt Medical Of Brooklyn Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184070625 PECOS PAC ID: 7315358413 Enrollment ID: O20201120002012 |
News Archive
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
Blue Cross Blue Shield Association and top executives from Blue Cross and Blue Shield companies around the country today committed to addressing the nation's growing opioid crisis with an executive-level committee that will investigate its impact on individuals, local communities and the healthcare system as a whole.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Romi Shah, MD 75 Crystal Run Rd Ste 135, Middletown, NY 10941-7009 Ph: (845) 333-7800 | Dr Romi Shah, MD 75 Crystal Run Rd Ste 135, Middletown, NY 10941-7009 Ph: (845) 333-7800 |
News Archive
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
Blue Cross Blue Shield Association and top executives from Blue Cross and Blue Shield companies around the country today committed to addressing the nation's growing opioid crisis with an executive-level committee that will investigate its impact on individuals, local communities and the healthcare system as a whole.
Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
› Verified 4 days ago
Kavneet Kaur, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Garnet Health Doctors, Pc, 707 E Main St, Middletown, NY 10940 Phone: 845-333-7575 Fax: 845-333-7201 | |
Dr. Parukutty M Krishnan, M.D Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 45 Ashley Ave, Middletown, NY 10940 Phone: 845-326-8074 Fax: 845-326-8003 | |
Dr. Lisa Ann Batson, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 155 Crystal Run Rd, Middletown, NY 10941 Phone: 845-703-6999 Fax: 845-703-6297 | |
Dr. Manouchehr Lavian, MD LLC Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 129 Wickham Ave, Middletown, NY 10940 Phone: 845-341-1805 Fax: 845-342-9218 | |
Dr. Joanne Tortomas Brodkin White, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 45 Ashley Ave, Middletown, NY 10940 Phone: 845-326-8074 | |
Howard Lam, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 45 Ashley Ave, Middletown, NY 10940 Phone: 845-326-8027 |